1. Home
  2. UVV vs BEAM Comparison

UVV vs BEAM Comparison

Compare UVV & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UVV
  • BEAM
  • Stock Information
  • Founded
  • UVV 1886
  • BEAM 2017
  • Country
  • UVV United States
  • BEAM United States
  • Employees
  • UVV N/A
  • BEAM N/A
  • Industry
  • UVV Farming/Seeds/Milling
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UVV Industrials
  • BEAM Health Care
  • Exchange
  • UVV Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • UVV 1.3B
  • BEAM 1.6B
  • IPO Year
  • UVV N/A
  • BEAM 2020
  • Fundamental
  • Price
  • UVV $58.25
  • BEAM $16.76
  • Analyst Decision
  • UVV
  • BEAM Strong Buy
  • Analyst Count
  • UVV 0
  • BEAM 11
  • Target Price
  • UVV N/A
  • BEAM $48.90
  • AVG Volume (30 Days)
  • UVV 263.9K
  • BEAM 1.8M
  • Earning Date
  • UVV 08-06-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • UVV 5.64%
  • BEAM N/A
  • EPS Growth
  • UVV N/A
  • BEAM N/A
  • EPS
  • UVV 3.78
  • BEAM N/A
  • Revenue
  • UVV $2,947,284,000.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • UVV N/A
  • BEAM N/A
  • Revenue Next Year
  • UVV N/A
  • BEAM $8.82
  • P/E Ratio
  • UVV $15.61
  • BEAM N/A
  • Revenue Growth
  • UVV 7.23
  • BEAM N/A
  • 52 Week Low
  • UVV $46.26
  • BEAM $13.53
  • 52 Week High
  • UVV $67.33
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • UVV 43.32
  • BEAM 44.29
  • Support Level
  • UVV $58.62
  • BEAM $16.18
  • Resistance Level
  • UVV $60.18
  • BEAM $18.33
  • Average True Range (ATR)
  • UVV 1.78
  • BEAM 1.10
  • MACD
  • UVV -0.49
  • BEAM 0.00
  • Stochastic Oscillator
  • UVV 7.35
  • BEAM 28.65

About UVV Universal Corporation

Universal Corp is a global leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segment includes Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: